240 related articles for article (PubMed ID: 26681196)
21. Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Altan B; Yokobori T; Ide M; Mochiki E; Toyomasu Y; Kogure N; Kimura A; Hara K; Bai T; Bao P; Suzuki M; Ogata K; Asao T; Nishiyama M; Oyama T; Kuwano H
Gastric Cancer; 2016 Jul; 19(3):789-97. PubMed ID: 26472729
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Impact of the Signet Ring Cell Type in Node-Negative Gastric Cancer.
Kong P; Wu R; Yang C; Geng Q; Liu J; Chen S; Liu X; Ye M; He W; Yang Q; Xia L; Xu D
Sci Rep; 2016 Jul; 6():26313. PubMed ID: 27381549
[TBL] [Abstract][Full Text] [Related]
23. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
24. The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer.
Zhang J; He XH; Xie XY; Hu X; He C
J Int Med Res; 2010; 38(2):423-31. PubMed ID: 20515556
[TBL] [Abstract][Full Text] [Related]
25. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.
Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Chung IJ
Gastric Cancer; 2011 Aug; 14(3):249-56. PubMed ID: 21431297
[TBL] [Abstract][Full Text] [Related]
27. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer.
Liu X; Zhang X; Zhang Z; Chang J; Wang Z; Wu Z; Wang C; Sun Z; Ge X; Geng R; Tang W; Dai C; Lin Y; Lin F; Sun M; Jia W; Xue W; Ji J; Hu Y; Qin G; Li J
Int J Cancer; 2017 Nov; 141(10):2093-2102. PubMed ID: 28722210
[TBL] [Abstract][Full Text] [Related]
28. Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer.
Hur H; Kim YB; Ham IH; Lee D
J Surg Oncol; 2015 Nov; 112(6):585-91. PubMed ID: 26381042
[TBL] [Abstract][Full Text] [Related]
29. [Long-term outcome and analysis of prognostic factors in 114 cases of postoperative stage III gastric cancer].
Zhang Y; Ma LW
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):863-6. PubMed ID: 24447487
[TBL] [Abstract][Full Text] [Related]
30. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
31. Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer.
Kim HW; Kim JH; Lim BJ; Kim H; Kim H; Park JJ; Youn YH; Park H; Noh SH; Kim JW; Choi SH
Ann Surg Oncol; 2016 Dec; 23(13):4344-4351. PubMed ID: 27469120
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and outcomes in patients undergoing radical resection for early gastric cancer with signet ring cell histology.
Wang Z; Zhang X; Hu J; Zeng W; Zhou Z
J Visc Surg; 2015 Dec; 152(6):357-61. PubMed ID: 26481069
[TBL] [Abstract][Full Text] [Related]
33. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
34. A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer.
Saito T; Kurashige J; Nambara S; Komatsu H; Hirata H; Ueda M; Sakimura S; Uchi R; Takano Y; Shinden Y; Iguchi T; Eguchi H; Ehata S; Murakami K; Sugimachi K; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S915-22. PubMed ID: 25986864
[TBL] [Abstract][Full Text] [Related]
35. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer.
Park HS; Jung M; Kim HS; Kim HI; An JY; Cheong JH; Hyung WJ; Noh SH; Kim YI; Chung HC; Rha SY
Ann Surg Oncol; 2015 Jan; 22(1):224-31. PubMed ID: 25081339
[TBL] [Abstract][Full Text] [Related]
36. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer.
Ji X; Yang Q; Qin H; Zhou J; Liu W
J Int Med Res; 2019 Jun; 47(6):2524-2532. PubMed ID: 31039658
[TBL] [Abstract][Full Text] [Related]
37. Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy.
Li XT; Tang L; Chen Y; Li YL; Zhang XP; Sun YS
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1237-47. PubMed ID: 25537963
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer.
Shi C; Yang B; Chen Q; Yang J; Fan N
Oncology; 2011; 80(5-6):289-95. PubMed ID: 21778768
[TBL] [Abstract][Full Text] [Related]
39. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
